RS53180B - Novel seh inhibitors and their use - Google Patents

Novel seh inhibitors and their use

Info

Publication number
RS53180B
RS53180B RS20140078A RSP20140078A RS53180B RS 53180 B RS53180 B RS 53180B RS 20140078 A RS20140078 A RS 20140078A RS P20140078 A RSP20140078 A RS P20140078A RS 53180 B RS53180 B RS 53180B
Authority
RS
Serbia
Prior art keywords
thiophenyl
pyridyl
phenyl
alkyl
seh inhibitors
Prior art date
Application number
RS20140078A
Other languages
Serbian (sr)
Inventor
Yun Ding
Reema K. Thalji
Joseph Paul Marino Jr.
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of RS53180B publication Critical patent/RS53180B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/46—Phenazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Jedinjenje Formule I:u kojoj:A je fenil, tiofenil ili piridil;R1 je nezvisno odabran iz grupe koju čine: halo, CN, OCF3, CF3, OC1-6alkil, morfolino, CO2H i N(CH3)2;n je 1, 2 ili 3;R2 je H;m je 1 ili 2;Z je O;B je cikloheksil;R4 je HY je C1-C3alkil, fenil, tiofenil, ili piridil; pri čemu fenil, tiofenil ili piridil može da bude supstituisan sa -CO2H, SO2Me, CF3, halo, ili CN;R5 je vodonik ili C1-C6alkil; iR6 je vodonik ili C1-C6alkil;njegova farmaceutski prihvatljiva so.Prijava sadrži još 17 patentnih zahteva.A compound of Formula I: wherein: A is phenyl, thiophenyl or pyridyl, R 1 is independently selected from the group consisting of: halo, CN, OCF 3, CF 3, OC 1-6 alkyl, morpholino, CO2H and N (CH 3) 2; n is 1, 2 or 3, R 2 is H, m is 1 or 2, Z is O, B is cyclohexyl, R 4 is HY is C 1 -C 3 alkyl, phenyl, thiophenyl, or pyridyl; wherein phenyl, thiophenyl or pyridyl may be substituted by -CO2H, SO2Me, CF3, halo, or CN, R5 is hydrogen or C1-C6alkyl; R 6 is hydrogen or C 1 -C 6 alkyl, a pharmaceutically acceptable salt thereof.

RS20140078A 2007-10-11 2008-10-10 Novel seh inhibitors and their use RS53180B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97915407P 2007-10-11 2007-10-11
PCT/US2008/079517 WO2009049157A1 (en) 2007-10-11 2008-10-10 Novel seh inhibitors and their use

Publications (1)

Publication Number Publication Date
RS53180B true RS53180B (en) 2014-06-30

Family

ID=40549589

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20140078A RS53180B (en) 2007-10-11 2008-10-10 Novel seh inhibitors and their use

Country Status (29)

Country Link
US (2) US8173805B2 (en)
EP (1) EP2214487B1 (en)
JP (1) JP5372943B2 (en)
KR (1) KR101546111B1 (en)
CN (1) CN101896065B (en)
AU (1) AU2008310732B2 (en)
BR (1) BRPI0817542A2 (en)
CA (1) CA2702265C (en)
CO (1) CO6270285A2 (en)
CR (1) CR11423A (en)
CY (1) CY1114865T1 (en)
DK (1) DK2214487T3 (en)
DO (1) DOP2010000101A (en)
EA (1) EA018414B1 (en)
ES (1) ES2445444T3 (en)
HK (1) HK1141211A1 (en)
HR (1) HRP20140105T1 (en)
IL (1) IL204889A (en)
MA (1) MA31761B1 (en)
MX (1) MX2010003942A (en)
MY (1) MY157116A (en)
NZ (1) NZ584471A (en)
PL (1) PL2214487T3 (en)
PT (1) PT2214487E (en)
RS (1) RS53180B (en)
SI (1) SI2214487T1 (en)
UA (1) UA107444C2 (en)
WO (1) WO2009049157A1 (en)
ZA (1) ZA201002465B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097378B1 (en) 2006-11-03 2012-09-12 GlaxoSmithKline LLC Novel seh inhibitors and their use
WO2009049165A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
KR101546111B1 (en) * 2007-10-11 2015-08-20 글락소스미스클라인 엘엘씨 Novel seh inhibitors and their use
FR2948027A1 (en) * 2009-07-17 2011-01-21 Merck Sante Sas DIHYDRO-1,3,5-TRIAZINE AMINO DERIVATIVES FOR THEIR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ISCHEMIA AND / OR REPERFUSION
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015104422A1 (en) 2014-01-13 2015-07-16 Basf Se Dihydrothiophene compounds for controlling invertebrate pests
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
US10308648B2 (en) * 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2020074549A1 (en) * 2018-10-10 2020-04-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
WO2024105234A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420283A (en) 1993-08-02 1995-05-30 Pfizer Inc. Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
WO2002004452A2 (en) 2000-07-07 2002-01-17 Neotherapeutics, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
KR100600550B1 (en) 2000-10-20 2006-07-13 에자이 가부시키가이샤 Nitrogenous aromatic ring compounds
US20020091133A1 (en) 2000-12-12 2002-07-11 Eve M. Taylor Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis
KR100909665B1 (en) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 Pyrazole Compounds Useful as Protein Kinase Inhibitors and Pharmaceutical Compositions Comprising the Same
EP1406892B1 (en) 2001-06-29 2007-09-05 Boehringer Ingelheim Pharmaceuticals Inc. Phenyl pyrazole derivatives as soluble epoxide hydrolase inhibitors
US20030055249A1 (en) 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN102151273B (en) 2002-02-05 2015-11-25 安斯泰来制药有限公司 2,4,6-triamino-1,3,5-triazine derivative
BR0310061A (en) 2002-05-16 2005-03-01 Pharmacia Corp Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions
EP1464335A3 (en) 2003-03-31 2007-05-09 Taisho Pharmaceutical Co. Ltd. Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
AU2004253962A1 (en) 2003-07-02 2005-01-13 Vertex Pharmaceuticals Incorporated Pyrimidines useful as modulators of voltage-gated ion channels
US7223759B2 (en) 2003-09-15 2007-05-29 Anadys Pharmaceuticals, Inc. Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
CN1902177A (en) 2003-09-22 2007-01-24 万有制药株式会社 Novel piperidine derivative
GB0401269D0 (en) 2004-01-21 2004-02-25 Astrazeneca Ab Compounds
US20060069110A1 (en) 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
AU2005316599A1 (en) 2004-12-14 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrimidine inhibitors of ERK protein kinase and uses therof
EP1885697A2 (en) 2005-05-06 2008-02-13 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
JP2009511489A (en) * 2005-10-07 2009-03-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors
CA2637620A1 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
TW200808723A (en) * 2006-03-13 2008-02-16 Univ California Conformationally restricted urea inhibitors of soluble epoxide hydrolase
EP2097378B1 (en) 2006-11-03 2012-09-12 GlaxoSmithKline LLC Novel seh inhibitors and their use
EP2217068A4 (en) 2007-10-11 2011-09-14 Glaxosmithkline Llc NOVEL sEH INHIBITORS AND THEIR USE
KR101546111B1 (en) 2007-10-11 2015-08-20 글락소스미스클라인 엘엘씨 Novel seh inhibitors and their use
WO2009049165A1 (en) 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2009048154A1 (en) 2007-10-12 2009-04-16 Nec Corporation Semiconductor device and method for designing the same
WO2009070497A1 (en) 2007-11-28 2009-06-04 Smithkline Beecham Corporation SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE
WO2009073772A1 (en) 2007-12-06 2009-06-11 Smithkline Beecham Corporation Novel seh inhibitors and their use
JP2011510997A (en) 2008-01-30 2011-04-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Novel sEH inhibitors and uses thereof
EP2240021A4 (en) 2008-01-30 2011-08-17 Glaxosmithkline Llc Novel seh inhibitors and their use
JP2011510998A (en) 2008-01-30 2011-04-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Novel sEH inhibitors and uses thereof
WO2010011917A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS

Also Published As

Publication number Publication date
CN101896065B (en) 2013-12-18
CN101896065A (en) 2010-11-24
AU2008310732A1 (en) 2009-04-16
HRP20140105T1 (en) 2014-03-14
ES2445444T3 (en) 2014-03-03
IL204889A0 (en) 2010-11-30
NZ584471A (en) 2012-01-12
WO2009049157A1 (en) 2009-04-16
CY1114865T1 (en) 2016-12-14
MA31761B1 (en) 2010-10-01
US20100210656A1 (en) 2010-08-19
US8212032B2 (en) 2012-07-03
MX2010003942A (en) 2010-04-30
IL204889A (en) 2014-08-31
UA107444C2 (en) 2015-01-12
KR20100075619A (en) 2010-07-02
EP2214487A4 (en) 2011-12-21
KR101546111B1 (en) 2015-08-20
EP2214487A1 (en) 2010-08-11
CA2702265C (en) 2014-12-02
HK1141211A1 (en) 2010-11-05
CR11423A (en) 2010-06-28
DK2214487T3 (en) 2014-02-10
AU2008310732B2 (en) 2012-03-08
JP5372943B2 (en) 2013-12-18
US20100249137A1 (en) 2010-09-30
CO6270285A2 (en) 2011-04-20
EP2214487B1 (en) 2013-11-27
ZA201002465B (en) 2010-12-29
PT2214487E (en) 2014-02-20
MY157116A (en) 2016-05-13
PL2214487T3 (en) 2014-04-30
EA201070442A1 (en) 2010-10-29
BRPI0817542A2 (en) 2014-10-07
SI2214487T1 (en) 2014-03-31
DOP2010000101A (en) 2010-07-31
CA2702265A1 (en) 2009-04-16
JP2011500594A (en) 2011-01-06
EA018414B1 (en) 2013-07-30
US8173805B2 (en) 2012-05-08

Similar Documents

Publication Publication Date Title
RS53180B (en) Novel seh inhibitors and their use
RS52261B (en) Amidophenoxyindazoles useful as inhibitors of c-met
RS54506B1 (en) Picolinamide derivatives as kinase inhibitors
RS50672B (en) Method for preparing n-phenylpyrazole-1-carboxamides
RS53348B (en) Process for making 3-substituted 2-amino-5-halobenzamides
RS51471B (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
RS53029B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
RS54260B1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
RS51949B (en) Kinase inhibitors
RS51674B (en) Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists
ME01421B (en) 5-substituted quinazolinone derivatives as antitumor agents
EA200701176A1 (en) NEW NAPHTHALINE COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HRP20080339T3 (en) N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
RS51280B (en) Novel hydantoin derivatives for the treatment of obstructive airway diseases
RS54700B1 (en) Benzodioxinyl substituted indazole derivatives
CR9830A (en) AMINO-5- [4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF B-SECRETASE
RS53688B1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
RS50378B (en) N-heterocyclic derivatives as nos inhibitors
DE602004008098D1 (en) SUBSTITUTED 2H-Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRAZINE AS GSK-3 INHIBITORS
RS50606B (en) Substituted morpholine and tiomorpholine derivatives
RS54552B1 (en) Diamino heterocyclic carboxamide compound
RS54661B1 (en) Substituted imidazopyridazines
RS52562B (en) (3-aryl-piperazin-1-yl) derivatives of 6,7-dialkoxyquinazoline, 6,7-dialkoxyphtalazine and 6,7-dialkoxyisoquinoline
NO20092770L (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
BRPI0906495B8 (en) indolyl-pyridone derivative compounds and pharmaceutical composition